MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study

    M. Zeissler, R. Windle, K. Raphael, G. Rafaloff, K. Mcfarthing, H. Matthews, C. Carroll (Plymouth, United Kingdom)

    Objective: To assemble an international, multi-stakeholder Delphi panel to seek consensus on trial methodology for an adaptive trial platform investigating disease modifying therapies (DMTs) in…
  • MDS Virtual Congress 2021

    Early versus later levodopa and onset of motor fluctuations in PD: Observations from the Parkinson’s Outcomes Project

    S. Chiu, A. Ramirez-Zamora, B. Patel, S. Wu, H. Gao, O. Nguyen, I. Malaty (Gainesville, USA)

    Objective: To characterize patients with early versus later levodopa exposure, defining “early” as within 2 years of Parkinson’s disease (PD) diagnosis, and to determine whether…
  • MDS Virtual Congress 2021

    THE EFFECT OF VITAMIN D IN PARKINSON’S DISEASE

    E. Göger, G. Yüksel, G. Gürsoy (İstanbul, Turkey)

    Objective: The objective of this study is to investigate the role of vitamin D deficiency (VDD) as an etiopathological factor in Parkinson's disease (PD). Background:…
  • MDS Virtual Congress 2021

    Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

    C. Labandeira, MG. Alonso Losada, R. Yáñez Baña, I. Cimas Hernando, I. Cabo López, JM. Paz González, MJ. González Palmás, C. Martínez Miró, D. Santos García (Vigo, Spain)

    Objective: Our aim was to analyze the effectiveness of safinamide on mood in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
  • MDS Virtual Congress 2021

    Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.

    S. Oda, Y. Saitoh, J. Takei, S. Watanabe, Y. Mukai, Y. Takahashi (Kodaira, Japan)

    Objective: To evaluate whether Helicobactor pylori (H.pylori) infection affects the pharmacokinetics of L-DOPA in patients with Parkinson’s disease (PD). Background: H. pylori infects gastric mucosa…
  • MDS Virtual Congress 2021

    Beta-antagonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies

    A. Singh, S. Hussain, B. Antony (Hobart, Australia)

    Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of β-antagonist and the risk of PD.…
  • MDS Virtual Congress 2021

    Comparison and analysis of pupillometer parameters between patients with drug naive Parkinson’s disease and controls

    S. You, J. Yoo (Daegu, Republic of Korea)

    Objective: We compared the pupillary findings of drug-naïve Parkinson’s disease (PD) patients and controls to investigate the characteristics of pupillary light reflexes (PLR) in PD…
  • MDS Virtual Congress 2021

    Sexual dysfunction in female patients with Multiple System Atrophy

    C. Raccagni, E. Indelicato, V. Sidoroff, M. Daniaux, A. Bader, B. Toth, L. Jelisejevas, A. Fanciulli, F. Leys, S. Eschlboeck, C. Kaindlstorfer, S. Boesch, G. Wenning (Innsbruck, Austria)

    Objective: To characterize sexual dysfunction in female patients with Multiple System Atrophy (MSA). Background: The diagnosis of probable MSA relies on the presence of parkinsonian…
  • MDS Virtual Congress 2021

    A retrospective review of clinical features of Progressive Supranuclear Palsy (PSP) in a movement disorders clinic

    G. Shepherd, T. Wongwarawipat, A. Chatterjee (Reading, United Kingdom)

    Objective: Understanding the common clinical features of PSP. Background: PSP is a relatively rare progressive neurodegenerative disease, which can often be difficult to distinguish from…
  • MDS Virtual Congress 2021

    Coffee, smoking and aspirin are associated with age at onset and clinical severity in idiopathic Parkinson’s disease

    C. Gabbert, I. König, T. Lüth, M. Kasten, A. Grünewald, C. Klein, J. Trinh (Lübeck, Germany)

    Objective: To investigate a possible association between smoking, the consumption of caffeine and the use of aspirin on age at onset (AAO), motor and non-motor…
  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley